Company and Stock Identity

How Neurophet Connects to the Public Market

Company structure
Private company, not independently verified
Market access
No current public listing was verified.
Research focus
Two things need checking before anyone relies on this one. First the regulatory status: outside reports describe United States clearances for the Alzheimer's product, and this site's own FDA directory holds no record under the Neurophet name, so look the product up in the federal database yourself rather than taking a press summary for it. Second the role the software plays. Measuring a brain scan to help decide whether a patient should start or stay on an Alzheimer's drug is a heavier job than flagging a scan for review, and the proof has to match. Because the company publishes nothing this desk can read, check every claim against the partner announcement it came from.

This is an honest gap, not a finding. Every page on the main Neurophet site returned an empty document to this desk on 2026-11-07, including the homepage, the English homepage and the investor relations page, so no listing, share count or legal structure could be read from the company itself. The one Neurophet host that opened is its hiring site, whose footer gives the Korean company name as Neurophet Inc. Search results outside the company describe a Korean exchange listing, which this desk could not confirm from either the company or an exchange page, so this record says no listing was verified rather than carrying an unchecked ticker. Every other fact in this profile comes from the hiring site or from the RapidAI partnership announcement of 2 November 2026, which names the company's products and its two chief executives. Checked on 2026-11-07.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... RapidAI ... Company source

Neurophet brain scan measurement joins the RapidAI platform for Alzheimer's and MS monitoring

In an announcement dated 2 November 2026 and carried on the RapidAI site, Neurophet and RapidAI said they had partnered to widen access to brain scan measurement for Alzheimer's disease and multiple sclerosis treatment monitoring. The announcement names the Neurophet products involved as AQUA AD Plus, SCALE PET, AQUA MS, AQUA and a research tool it calls tES/TMS LAB, and says they are designed to support treatment monitoring. It says the work reaches clinicians through the Rapid Enterprise Platform, Rapid Navigator Pro and the Rapid Mobile App, and it names the two Alzheimer's treatments Leqembi and Kisunla as the context for the monitoring. Neurophet co-chief executives Jake Junkil Been and Donghyeon Kim are quoted, as is RapidAI founder Dr. Greg Albers. The announcement makes no claim of FDA clearance, states no K number and names no CE marking, and it reports no patient numbers and no accuracy figures.

Why it matters: This one matters because of what the new Alzheimer's drugs created, which is a monitoring workload rather than a reading backlog. A patient on one of these treatments needs brain scans compared over time and specific changes watched for, and that is measurement work rather than spotting a finding. Hospitals that take on these drugs have to find that capacity somewhere. Putting the measurement on a platform the hospital already runs is the cheap way in, and that is the real content of the announcement. Be careful with two things. The announcement claims no regulatory status for any of the named products, and this site's own FDA directory holds no record under the Neurophet name, so treat these as tools described by their makers until you check the federal record yourself. And designed to support treatment monitoring is a sentence about intent, not evidence. Nothing here reports how the measurements compare with a specialist reading the same scans.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The hiring site was the only Neurophet page that would open on 2026-11-07. The roles it listed are commercial and field facing rather than research: a medical director post for a specialist physician, a business development representative, a Japan sales representative, a head of sales for Japan at director level, and a field service engineer in the United States. It names a Seoul head office with operations in Japan and the United States, and gives no team size.

Qualification signal: The open roles say this company is selling abroad, not building at home, so the signal is having taken an imaging product into a new country: regulatory filing, local distribution, and hospital installation. For the medical director role, experience with Alzheimer's treatment decisions matters more than imaging alone, because the software is used around a drug. Ask which market a role actually covers, since Seoul, Tokyo and the United States are three different jobs here.

Check current roles at Neurophet. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources